Latest news with #AHEAD
Time of India
13-07-2025
- Politics
- Time of India
All about Skynex, Ukraine's new 'Made in Germany' drone killers that fires 1,000 rounds per minute
Ukraine has released videos of its new drone killers, the German-made Skynex air defense systems, which are proving crucial in intercepting Russian Shahed drones . As per Ukraine's Air Force Command, the Rheinmetall-developed Skynex short-range air defense (SHORAD) system has been consistently effective in neutralizing incoming unmanned aerial vehicles (UAVs). Though the exact locations of the latest intercepts remain undisclosed, reports claimed that the system's performance exceeded expectations during one of Ukraine's most intense drone defense operations to date. — XiXiDu (@XiXiDu) by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo Reportedly on the night of July 11–12, Ukrainian air defense units downed 319 Shahed drones and 25 cruise missiles. The newly released video shows Skynex in action, intercepting at least seven drones with rapid precision. All about Skynex Introduced in 2021 by German defense giant Rheinmetall, Skynex is specifically designed to counter drones, cruise missiles, and precision-guided threats. In Ukraine, it's deployed to defend key infrastructure, such as airfields and critical facilities. Live Events — Zn_Portnova (@Zn_Portnova) At the heart of Skynex is the Oerlikon Mk3 — a 35mm automatic cannon that can fire up to 1,000 rounds per minute, with an effective range of 4 kilometers. It uses advanced AHEAD (Advanced Hit Efficiency and Destruction) ammunition, which explodes in mid-air to unleash sub-projectiles that destroy aerial targets like drones. Each Skynex battery includes four gun modules, a command post, and a radar unit for target detection and coordination. Each gun is equipped with its own radar and electro-optical targeting system, allowing for autonomous threat engagement. Rheinmetall emphasizes that the cost-effective AHEAD rounds—estimated at about €4,000 per engagement—are ideal against swarms of low-cost drones and are less vulnerable to electronic jamming compared to missile-based systems like IRIS-T. Germany reportedly sold two Skynex systems to Ukraine in 2024 at a cost of €182 million. These remain the only operational Skynex units in use anywhere in the world.
Business Wire
26-06-2025
- Business
- Business Wire
Accelerating the Software Development Lifecycle: Windsurf and AHEAD Forge Strategic AI Partnership
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Windsurf, the enterprise-grade AI development platform, today announced a strategic partnership with AHEAD, a leading provider of cloud, data, and modernization solutions. AHEAD now offers a full suite of services around Windsurf, including implementation, managed services, AI advisory, and outcome-based analytics—giving enterprise teams a direct path to adopting AI across the entire software development lifecycle. 'Large enterprise engineering teams are moving beyond AI experimentation. They're now focused on end-to-end transformation,' said Anshul Ramachandran, Founding Team at Windsurf. 'AHEAD brings the expertise to help these teams navigate complex DevOps environments. Together, we can implement Windsurf in highly specialized settings where tailored solutions matter most.' A Complete DevOps Offering As part of its broader playbook, AHEAD brings a dedicated Windsurf services practice to the partnership, with certified experts delivering: Implementation and onboarding across enterprise teams and regulated environments Ongoing managed services and platform optimization AI advisory for integrating agentic development into broader engineering strategies Outcome-based analytics to tie software delivery velocity to business impact That said, AHEAD is not only delivering Windsurf to clients nationwide but actively leveraging it across its own modernization programs, creating, validating, and scaling AI-powered workflows in real time. 'At AHEAD, we recognize the value that AI-powered development holds for productivity, security, and compliance,' said Josh Perkins, VP of Emerging Technology at AHEAD. 'We're leveraging Windsurf's AI development tools to move the needle on business outcomes not only for clients, but for our own internal use cases as well. It's not just about faster coding, it's about transforming how enterprises approach software delivery.' Complementing the SDLC Today, Windsurf's agentic assistance is directly embedded in developer workflows at Fortune 500 companies and large regulated enterprises, where it has increased developer velocity by more than 50% and raised code acceptance rates by up to 80%. By integrating Windsurf alongside best-in-class tools, AHEAD provides a comprehensive solution for enterprises looking to: Automate core development tasks with AI agents Streamline legacy-to-cloud modernization programs Improve DevOps throughput while maintaining governance This partnership brings AI-powered software delivery to industries like healthcare, financial services, logistics, and more. By combining Windsurf's secure platform with AHEAD's expertise, enterprises can automate development tasks, speed up delivery timelines, and improve compliance at scale. About Windsurf Windsurf is a leader in AI-powered coding solutions, offering tools like the Windsurf Editor that blend collaborative, continuous AI assistance with developers' workflows, fundamentally changing how AI and humans work together. Designed for optimal flexibility, Windsurf supports over 70 languages and integrates with over 40 Integrated Developer Environments (IDEs), enabling developers to build and deploy applications more efficiently. Learn more at About AHEAD AHEAD builds platforms for digital business. Combining cloud-native capabilities in software and data engineering with an unparalleled track record of modernizing infrastructure, we're uniquely positioned to help accelerate the promise of digital transformation. Learn more at and follow us on Twitter at @ahead.
Iraqi News
15-06-2025
- Health
- Iraqi News
First Iraqi Medical Congress in London tackles healthcare future, uniting global expertise
London, UK ( – The inaugural Iraqi Medical Congress (IQMC 2025) officially launched in London this week, initiating a vital scientific dialogue on the current state and future of healthcare in Iraq. Announced by the Iraqi Embassy, the event serves as a crucial networking platform, bringing together the expertise of Iraqi medical professionals from within the country and across the diaspora to strengthen a healthcare system built on collaboration and shared knowledge. The opening session, attended by the Iraqi Ambassador to the United Kingdom, featured contributions from a host of Iraqi medical experts. The keynote lecture by Dr. Jaffar Allawi addressed the major challenges in managing diabetes in Iraq, setting a forward-thinking tone for the congress. He emphasized that effective treatment must begin with early diagnosis and lifestyle changes, not medication alone, underscoring the need to build a fair and efficient healthcare system rooted in prevention. A key partner in the event, the Authority of Health and Medical Education (AHEAD), affiliated with the Holy Shrine of Imam Hussain and the Gold Sponsor of IQMC 2025, reaffirmed its commitment to advancing healthcare in Iraq through education and innovation. AHEAD's involvement, representing a network of over 25 hospitals and universities, highlights a strong push from within Iraq to develop a more sustainable local healthcare system. Specialized frontiers and systemic solutions The congress delved into specialized fields with high-level presentations. Professor Mohammed Sami Al-Abbadi, President of IQMC and a consultant dermatologist, focused on advancements in dermatology and cosmetics. He highlighted the role of technology in enhancing diagnosis and stressed the importance of integrating cosmetic practices within a disciplined scientific and ethical framework to ensure patient safety amidst the specialty's rapid expansion. In another key session, ophthalmology expert Professor Moemen Al Reefy discussed the latest innovations in everyday eye care, from early diagnostic techniques to laser therapies. He emphasized that improving eye health across Iraq depends not only on technology but also on training medical staff and raising public awareness about early diagnosis. A pivotal discussion on health insurance featured a panel including Dr. Yasser Haba, Dr. Hani Al-Akbi, Dr. Yasir Sabri, and Dr. Majid Shingali. They framed health insurance as a critical need and opportunity for Iraq, despite challenges like weak administrative infrastructure and high medication prices. The panel concluded with key recommendations for building an effective system, including enacting inclusive legislation that guarantees coverage for all, creating a unified health database, ensuring fair drug pricing, and linking providers to a smart oversight system based on transparent performance indicators. The first Iraqi Medical Congress in London successfully brought together influential voices to not only discuss cutting-edge medical advancements but also to lay the groundwork for systemic reforms. The shared belief in collaboration between local and diaspora experts emerged as the key theme, fostering a unified vision for a sustainable and inclusive healthcare future for all Iraqis.
Cision Canada
26-05-2025
- Health
- Cision Canada
Empowering Canadians with type 2 diabetes: Program highlights the power of education and allied health Français
BURLINGTON, ON, May 26, 2025 /CNW/ - New outcomes from Boehringer Ingelheim Canada's Access for Health Education and Disease Management (AHEAD) program underscores the essential role that allied health professionals and disease management education play in the lives of Canadians living with type 2 diabetes (T2D). According to a 2025 survey, Boehringer's innovative national program, AHEAD, has helped patients become active partners in their care by improving their understanding and self-management of their own health conditions. "The program has been instrumental in enhancing patient education at our clinic. Having resources on-site, where patients are comfortable and familiar with the staff, has removed barriers to access and created a positive patient experience," said Dr. Matthew D'Mello, Community Family Physician at the Glazier Medical Clinic in Oshawa, Ontario. A survey of the participating allied healthcare professionals revealed that 97 per cent of respondents felt the AHEAD program addressed a specific gap or need, with patients reporting an 88 per cent improvement in their quality of life and a 92 per cent enhancement in disease management. AHEAD was implemented in over 70 primary and specialty care clinics across Canada for the duration of 2024, reaching about 3,200 patients. The program focused on optimizing disease management through guideline-directed medical therapy, seeking to improve health outcomes with the potential to reduce rehospitalization rates, and decrease emergency department visits. Educators offered culturally diverse, accessible support, allowing participants to receive care how and where it was most impactful for them. "I am grateful for the incredible opportunity provided by the AHEAD program. It has enabled me to educate patients about their diabetes focusing on self-management, setting realistic goals, identifying individual barriers, and offering solutions to positively impact their health journeys," said Mrudula Golla, a pharmacist and diabetes educator in Oshawa, Ontario "We are excited to see the implementation of the AHEAD program has succeeded in addressing the needs of people living with type 2 diabetes," says Dr. Rasha Eldesouky Abouelabbas, Vice President, Medical and Regulatory Affairs Boehringer Ingelheim Canada. "As a system collaborator, Boehringer is proud to continue investing in programs like AHEAD to address critical gaps in the healthcare system, making a meaningful impact in the lives of patients and the system as a whole." Boehringer Ingelheim (Canada) Ltd. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 500 people across Canada. Learn more at
Yahoo
26-05-2025
- Health
- Yahoo
Empowering Canadians with type 2 diabetes: Program highlights the power of education and allied health
BURLINGTON, ON, May 26, 2025 /CNW/ - New outcomes from Boehringer Ingelheim Canada's Access for Health Education and Disease Management (AHEAD) program underscores the essential role that allied health professionals and disease management education play in the lives of Canadians living with type 2 diabetes (T2D). According to a 2025 survey, Boehringer's innovative national program, AHEAD, has helped patients become active partners in their care by improving their understanding and self-management of their own health conditions. "The program has been instrumental in enhancing patient education at our clinic. Having resources on-site, where patients are comfortable and familiar with the staff, has removed barriers to access and created a positive patient experience," said Dr. Matthew D'Mello, Community Family Physician at the Glazier Medical Clinic in Oshawa, Ontario. A survey of the participating allied healthcare professionals revealed that 97 per cent of respondents felt the AHEAD program addressed a specific gap or need, with patients reporting an 88 per cent improvement in their quality of life and a 92 per cent enhancement in disease management. AHEAD was implemented in over 70 primary and specialty care clinics across Canada for the duration of 2024, reaching about 3,200 patients. The program focused on optimizing disease management through guideline-directed medical therapy, seeking to improve health outcomes with the potential to reduce rehospitalization rates, and decrease emergency department visits. Educators offered culturally diverse, accessible support, allowing participants to receive care how and where it was most impactful for them. "I am grateful for the incredible opportunity provided by the AHEAD program. It has enabled me to educate patients about their diabetes focusing on self-management, setting realistic goals, identifying individual barriers, and offering solutions to positively impact their health journeys," said Mrudula Golla, a pharmacist and diabetes educator in Oshawa, Ontario "We are excited to see the implementation of the AHEAD program has succeeded in addressing the needs of people living with type 2 diabetes," says Dr. Rasha Eldesouky Abouelabbas, Vice President, Medical and Regulatory Affairs Boehringer Ingelheim Canada. "As a system collaborator, Boehringer is proud to continue investing in programs like AHEAD to address critical gaps in the healthcare system, making a meaningful impact in the lives of patients and the system as a whole." Boehringer Ingelheim (Canada) Ltd. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 500 people across Canada. Learn more at SOURCE Boehringer Ingelheim Canada Ltd. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
